Cost-Effectiveness of Adding Web-Based Cognitive-Behavioral Therapy (CBT) to Luvox CR for Obsessive Compulsive Disorder (OCD)

Inclusion Criteria: * Men and women aged 18 years, with OCD of at least 1 year's duration, meeting DSM-IV diagnostic criteria, and having a baseline Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of 18. Exclusion Criteria: * Pregnant or nursing women or women of childbearing age not using an effective contraceptive method * Organic mental disorder * Bipolar disorder * Psychotic disorder * History of substance abuse or dependence within 3 years of evaluation for study * Major depression with suicidal risk * Major depression dominating the clinical picture * Panic disorder * Personality disorder severe enough to interfere with cooperation with study procedures * Need for antipsychotic medication * Depot neuroleptic drug within 6 months * Fluoxetine within 5 weeks * An MAOI within 2 weeks, any nightly sedative, or taking a medication that may interact with fluvoxamine * Serious or unstable medical condition (hematological, endocrine, cardiovascular, renal or gastrointestinal), a history of malignancy (other than excised basal cell carcinoma), history of brain disease, including more than one childhood febrile convulsion and all forms of epilepsy; or, are receiving behavior therapy for OCD. * Subjects who qualify for the study while taking an SSRI must have been taking their current dose or a higher dose for at least 12 weeks prior to study baseline. * Subjects who qualify for the study while taking fluvoxamine must be taking no more than 150 mg/day and never had a trial at a higher dose, must be believed by the investigator to be able to tolerate an increase to 250 mg/day starting at baseline, and must have been taking their pre-study dose or a higher dose (up to 150 mg/day) for at least 12 weeks prior to study baseline.